New warning label excluded from Zometa trial 
Published: April 18, 2011
Tags: Novartis, ONJ, osteonecrosis, product liability, Zometa
A product liability plaintiff could not introduce evidence that the defendant added a new warning label to the osteoporosis drug that allegedly injured her husband, a U.S. District Court in New York has ruled in granting a motion in limine.
Class action tolling preserves Zometa claim
By:
Pat Murphy
Published: January 14, 2011
Tags: class action, osteonecrosis, products liability, statute of limitations, Zometa
The doctrine of class action tolling applied to preserve the product liability lawsuit of a woman who claimed she suffered osteonecrosis of the jaw as a result of taking the prescription drug Zometa, the Montana Supreme Court has ruled.
Drug company hit with $13 million failure-to-warn verdict
By:
Sylvia Adcock
Published: December 3, 2010
Tags: Aredia, failure to warn, Novartis, osteonecrosis, product liability, Zometa
A federal jury in North Carolina has returned a verdict of nearly $13 million against pharmaceutical giant Novartis, saying the company failed to adequately warn patients and doctors about the risks of taking the bone-strengthening drugs Zometa and Aredia.
Zometa claims can go forward
By:
Pat Murphy
Published: March 13, 2010
Tags: Aredia, drug litigation, product liability, Zometa
A state presumption in favor of manufacturers does not apply to defeat product liability claims brought by plaintiffs who alleged they suffered severe jaw deterioration after taking the defendant’s bone-strengthening drugs, a U.S. District Court in Tennessee has ruled in denying a motion for summary judgment.
Woman awarded $3.2M in Zometa trial
By:
Pat Murphy
Published: October 22, 2009
Tags: product liability, Zometa
A Montana jury on Wednesday awarded $3.2 million to a woman suing the maker of a bone-strengthening drug in a decision that could have a bearing on hundreds of cases against the company nationwide.
Zometa trial could have national significance
By:
Pat Murphy
Published: October 19, 2009
Tags: Zometa
A lawsuit against a Swiss pharmaceutical company went to trial last week in Montana, but a verdict in the case could have national significance for hundreds of plaintiffs suing the company in a mass tort. Peggy L. Stevens of Missoula developed severe dental and jaw-related problems after taking Zometa, a bone-strengthening medication manufactured by Novartis. Her attorneys say the company knew patients taking Zometa were vulnerable to a degenerative jaw disorder called osteonecrosis, particularly those patients who undergo invasive dental procedures, like root canals or tooth extractions.
NEW FREE WHITE PAPER: E-Discovery
This FREE e-report brought to you by Lawyers USA contains the latest tips for conducting thorough and successful electronic discovery for your trial in 2012. We’ve analyzed the latest court rulings and trends in e-discovery to help you and your clients avoid sanctions and win your case.
Click here to get your free White Paper today!
